Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 for BJJ Injury Recovery Research: Injury Type Comparison

Partial MCL/LCL tear (Grade 1–2) 6–8 weeks to return to grappling Increases VEGF expression in ligament tissue; promotes Type I collagen deposition during proliferative phase Rats with induced MCL injury showed 50% faster return of tensile strength at day 14 (

This comparison does not assign a generated winner or score.

  • Partial MCL/LCL tear (Grade 1–2)
  • 6–8 weeks to return to grappling
  • Increases VEGF expression in ligament tissue; promotes Type I collagen deposition during proliferative phase
  • Rats with induced MCL injury showed 50% faster return of tensile strength at day 14 (Journal of Orthopaedic Research, 2011)
  • Most promising application. Ligament injuries benefit directly from angiogenesis stimulation in poorly vascularized tissue
  • Biceps/rotator cuff tendinopathy
  • 8–12 weeks of modified training
  • Modulates inflammatory cytokines (reduces IL-6, TNF-alpha); accelerates fibroblast migration to injury site
  • BPC-157-treated rats showed 40% reduction in inflammatory markers at day 7 post-tendon injury (European Journal of Pharmacology, 2018)
  • Strong mechanistic rationale. Tendon inflammation benefits from early inflammatory resolution
  • Shoulder labral fraying
  • 12–16 weeks conservative management or surgical repair
  • Promotes fibrocartilage formation; increases growth factor concentration at injury margins
  • Limited direct labral injury models; extrapolated from cartilage repair studies showing accelerated chondrocyte activity
  • Moderate evidence. Labral tissue heals slowly; angiogenesis may support peripheral repair but central labrum remains avascular
  • Chronic joint capsule inflammation (elbow, knee)
  • Ongoing management; resolution timelines vary widely
  • Reduces capsular fibrosis; modulates mast cell degranulation and histamine release
  • BPC-157 administration reduced capsular thickening by 35% in arthritis models (Journal of Physiology and Pharmacology, 2016)
  • Promising for chronic inflammation. Consistent anti-fibrotic effects across multiple joint models
More references

Related material